最终结果:IL-2对hiv感染患者没有益处。白细胞介素-2可以改善接受抗逆转录病毒治疗的患者的cd4细胞恢复，但这种益处并不能降低患病或死亡的风险。

Journal watch. AIDS clinical care Pub Date : 2010-01-01 DOI:10.1056/AC201001040000006

Charles B Hicks

{"title":"最终结果:IL-2对hiv感染患者没有益处。白细胞介素-2可以改善接受抗逆转录病毒治疗的患者的cd4细胞恢复，但这种益处并不能降低患病或死亡的风险。","authors":"Charles B Hicks","doi":"10.1056/AC201001040000006","DOIUrl":null,"url":null,"abstract":"For years, researchers have tried to find ways to incorporate interleukin (IL)-2 into HIV management, given its positive effects on CD4-cell counts. However, two large trials this year — SILCAAT and ESPRIT — demonstrated that those positive effects do not translate into …","PeriodicalId":88277,"journal":{"name":"Journal watch. AIDS clinical care","volume":"3 1","pages":"4"},"PeriodicalIF":0.0000,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Definitive results: IL-2 does not benefit HIV-infected patients. Interleukin-2 improves CD4-cell recovery in patients on antiretroviral therapy, but that benefit does not translate into lower risks for disease or death.\",\"authors\":\"Charles B Hicks\",\"doi\":\"10.1056/AC201001040000006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"For years, researchers have tried to find ways to incorporate interleukin (IL)-2 into HIV management, given its positive effects on CD4-cell counts. However, two large trials this year — SILCAAT and ESPRIT — demonstrated that those positive effects do not translate into …\",\"PeriodicalId\":88277,\"journal\":{\"name\":\"Journal watch. AIDS clinical care\",\"volume\":\"3 1\",\"pages\":\"4\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal watch. AIDS clinical care\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1056/AC201001040000006\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal watch. AIDS clinical care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1056/AC201001040000006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

多年来，鉴于白细胞介素(IL)-2对cd4细胞计数的积极作用，研究人员一直试图找到将其纳入艾滋病毒管理的方法。然而，今年的两项大型试验——SILCAAT和ESPRIT——表明，这些积极的效果并没有转化为……

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Definitive results: IL-2 does not benefit HIV-infected patients. Interleukin-2 improves CD4-cell recovery in patients on antiretroviral therapy, but that benefit does not translate into lower risks for disease or death.

For years, researchers have tried to find ways to incorporate interleukin (IL)-2 into HIV management, given its positive effects on CD4-cell counts. However, two large trials this year — SILCAAT and ESPRIT — demonstrated that those positive effects do not translate into …

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal watch. AIDS clinical care

自引率

0.00%

发文量